Centessa Pharmaceuticals plc reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders and related neurological conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.